Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered virus takes on tumors in first human trial

NCT ID NCT06171178

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This early-phase study tested a lab-modified virus (ASP1012) designed to infect and kill cancer cells while alerting the immune system. It involved 15 adults with advanced solid tumors who had exhausted standard treatments. Some participants also received the immunotherapy pembrolizumab. The main goals were to check safety and find the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Emory Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Gabrail Cancer and Research Center

    Canton, Ohio, 44718, United States

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • University of Iowa Hospitals

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.